Dapoxetine DC Granules are pharmaceutical formulation granules containing Dapoxetine Hydrochloride in a controlled granular format intended for direct-compression applications. Dapoxetine is a selective serotonin reuptake inhibitor used in pharmaceutical formulations, and the hydrochloride salt is commonly used as the active ingredient in finished oral formulations.
The DC designation refers to Direct Compression, a tablet manufacturing approach in which a suitable powder or granular formulation is compressed directly into tablets. For a DC product, the physical characteristics of the finished granules are important because particle size, flowability, density, compressibility, compactability and blend uniformity can influence manufacturing performance. Pharmaceutical research identifies flow and compactability as important properties for successful direct-compression formulation development.
Dapoxetine DC Granules are a granulated pharmaceutical formulation containing Dapoxetine Hydrochloride together with selected excipients. The granular format is intended to provide controlled physical characteristics suitable for formulation processing and compression.
Unlike the API itself, finished Dapoxetine DC Granules are a formulation system. Their characteristics depend on the API properties, excipient selection, granulation or particle-engineering process, particle-size distribution, moisture content and other manufacturing variables.
The finished granules can therefore be evaluated for both chemical quality and physical processing characteristics.
Dapoxetine Hydrochloride is the hydrochloride salt form of dapoxetine used as the active pharmaceutical ingredient in pharmaceutical formulations. The exact solid form, CAS number, molecular formula and molecular weight entered into the product database should correspond to the approved raw-material specification used for manufacturing.
For a finished Dapoxetine DC Granules product, API identity and strength should be established using a validated analytical procedure. The assay of the raw API should not automatically be copied as the assay specification of the finished granules because the finished formulation contains additional excipients.
Direct compression is used to manufacture tablets by compressing a suitable formulation blend without a conventional wet-granulation operation. The success of direct compression depends strongly on the physical properties of the formulation materials.
Research on pharmaceutical particle engineering shows that excipient properties such as flow and compactability are important to direct-compression performance.
Dapoxetine DC Granules can therefore be developed with attention to:
The actual acceptance limits should be established from the approved product specification.
Particle-size distribution is an important characteristic of Dapoxetine DC Granules because it can influence material flow, packing, blend uniformity and compression behavior.
The finished product may be characterized using D10, D50 and D90 measurements together with a defined granule-size range.
Particle-size limits should be based on the actual manufacturing process and product specification. Numerical D10, D50 or D90 values should not be presented as universal values without product-specific analytical data.
Controlled particle characteristics can also help maintain consistency between batches during pharmaceutical manufacturing.
Good flow is important for consistent transfer of granules and uniform die filling during tablet compression.
Dapoxetine DC Granules may be evaluated using:
These parameters provide information about the physical handling characteristics of the granules.
Research into direct-compression materials demonstrates that particle engineering can be used to improve powder flow and compaction behavior.
The appropriate numerical acceptance criteria should be taken from the actual finished-product specification.
Compressibility and compactability are important considerations for Dapoxetine DC Granules intended for tablet manufacturing.
Compressibility describes the reduction in powder volume under applied pressure, while compactability describes the ability of the material to form a mechanically strong compact.
Finished-product development may evaluate:
These characteristics depend on the complete formulation and manufacturing process and should not be presented as universal specifications for every Dapoxetine DC Granules grade.
Scientific approaches such as compression-behavior classification and SeDeM-based assessment are used to evaluate material suitability for direct-compression formulation development.
Content uniformity is particularly important for formulations containing an active ingredient at relatively low concentration.
Uniform distribution of Dapoxetine Hydrochloride throughout the granulated formulation can be evaluated using an appropriate validated analytical method and sampling procedure.
Particle engineering and carrier-based approaches have been investigated to improve content uniformity in low-dose direct-compression formulations.
For Dapoxetine DC Granules, the actual acceptance criteria should be established according to the finished formulation, manufacturing process and applicable quality requirements.
The dissolution behavior of a finished Dapoxetine formulation depends on the API characteristics, particle size, excipient composition, granule structure, compression conditions and other formulation variables.
Dapoxetine DC Granules may therefore be evaluated during formulation development for dissolution and release performance.
Specific dissolution percentages or time points should not be stated as universal product specifications unless they are supported by the validated finished-product method and approved specification.
Moisture content can influence the physical characteristics of pharmaceutical granules and may affect flow, compression and storage stability.
For Dapoxetine DC Granules, moisture should be controlled according to the approved product specification and supported by stability data.
Packaging and storage conditions should likewise be established according to validated stability requirements and the characteristics of the finished formulation.
Dapoxetine DC Granules may be evaluated for oral solid dosage formulations where a controlled granular formulation is required for direct compression.
Potential formulation-development applications include:
The final formulation composition and processing conditions should be established through formulation development and validation.
Quality control of Dapoxetine DC Granules should address both chemical and physical quality attributes.
Typical quality-control parameters may include:
The exact analytical methods and acceptance limits should be taken from the approved finished-product specification.
Physical properties are particularly relevant for DC products because material characteristics can affect feeding, die filling, compression and final tablet quality.
Development of Dapoxetine DC Granules can involve systematic evaluation of API and excipient properties.
Important development studies may include:
The optimal formulation and processing parameters should be established using product-specific development data.
Dapoxetine DC Granules may be considered for:
The specific application and performance should be established through formulation development and validated manufacturing studies.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white granules |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Water Content | NMT 1.0% |